ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1727

Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice

Sheri Saunders, Garth Blackler, Patti Kiser, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada

Meeting: ACR Convergence 2023

Keywords: Animal Model, Anti-citrullinated Protein Autoantibodies (ACPAs), citrullination, rheumatoid arthritis, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1713–1733) RA – Animal Models Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Most rheumatoid arthritis (RA) patients express autoantibodies to post-translationally modified antigens, including citrullinated and homocitrullinated (also known as carbamylated) peptides. Homocitrulline and citrulline are structurally similar and immune responses to peptides containing either of these modifications are cross-reactive. Citrullinated peptides bind strongly to MHCII molecules containing a consensus sequence called the Shared Epitope (encoded by HLA-DRB1 alleles, the strongest genetic risk factor for RA). The relationship between homocitrullinated peptides and the Shared Epitope remains unclear. The aim of this study is to determine whether homocitrullinated peptides induce arthritis in a humanized mouse model of RA expressing the Shared Epitope.

Methods: Male and female HLA-DRB1*04:01-transgenic (DR4tg) mice and wild-type C57Bl/6 (B6) mice were immunized with a synthetic homocitrullinated peptide (HomoCitJED) or PBS and then received intra-articular (i.a.) HomoCitJED in one knee and PBS in the other knee. Immune responses in these mice were measured serially for serum autoantibody production by ELISA to the following antigens: HomoCitJED, CitJED (a synthetic citrullinated peptide that contains the same backbone as HomoCitJED), homocitrullinated fibrinogen (HomoCitFib), citrullinated fibrinogen (CitFib), fibrinogen (Fib) and cyclic citrullinated protein/peptide 2 (CCP2).Arthritis was assessed by serial measurements of joint swelling with calipers and by histopathology at sacrifice (day 137 post-primary immunization) using a standardized scoring system.

Results: After immunization with HomoCitJED, all DR4tg mice (14/14) developed IgG anti-HomoCitJED and anti-HomoCitFib antibodies, compared to 4/6 and 3/6 B6 mice, respectively. A small number of mice developed antibodies to CitJED (4/14 DR4tg and 1/6 B6). Anti-CCP2 was detected in 8/14 DR4tg and 4/6 B6 mice. None of the mice had detectable antibodies to Fib or CitFib. Antibody levels did not change significantly after i.a. injections and over time. PBS immunized mice did not have detectable immune responses or arthritis. After day 78 post-immunization, significant joint swelling was observed in the knees of HomoCitJED injected DR4tg mice with an arthritis score of 3.92 (SD 2.90)/12 versus 1.18 (SD 1.08)/12 in HomoCitJED-injected B6 wild-type mice; p=0.0016. Histopathologic findings included synovial thickening and pannus, hypervascularity, cartilage destruction and bone erosions.

Conclusion: Mice expressing human Shared Epitope developed immune responses to homocitrullinated and citrullinated antigens and RA-like arthritis. These findings support an arthritogenic role for homocitrullinated antigens that is enhanced by the Shared Epitope.


Disclosures: S. Saunders: None; G. Blackler: None; P. Kiser: None; E. Cairns: None; L. Barra: AstraZeneca, 1, GlaxoSmithKlein(GSK), 1, 6, Otsuka, 1, 5, 6, Pfizer, 1, 5, 6.

To cite this abstract in AMA style:

Saunders S, Blackler G, Kiser P, Cairns E, Barra L. Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/arthritogenicity-of-homocitrullinated-peptides-in-hla-drb1-transgenic-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/arthritogenicity-of-homocitrullinated-peptides-in-hla-drb1-transgenic-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology